Core Insights - Corcept Therapeutics and Amicus Therapeutics reported Q3 2025 results, showcasing contrasting profitability levels within the rare disease biotech sector [1] Company Summaries Corcept Therapeutics - Corcept Therapeutics is positioned as a profitable entity within the rare disease biotech space, indicating strong financial performance [1] Amicus Therapeutics - Amicus Therapeutics, in contrast, is highlighted as being at the opposite end of the profitability spectrum, suggesting challenges in achieving financial stability [1]